The White House Office of Science and Technology Policy (OSTP) have recently made a national call to action for new public and private commitments to support microbiome science.
“The need for interdisciplinary research, new tools, and common standards to foster groundbreaking discoveries about microbiomes is essential to make progress in understanding and, eventually, managing microbiomes in all ecosystems,” the White House have said.
We spoke to Stephen OHara, CEO of OptiBiotix Health Plc who said ‘There is now growing industry and US national interest in the role of the microbiome in improving health. This ‘call to action’ by the US government will help accelerate funding an interest in this exciting space’.
OptiBiotix Health Plc has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
